iBio, Inc. 1,530,769 Shares of Common Stock (par value $0.001 per share) Pre- Funded Warrants to Purchase 1,834,616 Shares of Common Stock Series A Warrants to Purchase 3,365,385 Shares of Common Stock and Series B Warrants to Purchase 3,365,385...Lock-Up Agreement • December 8th, 2022 • iBio, Inc. • Pharmaceutical preparations • New York
iBio, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 1,530,769 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), and (b) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,834,616 shares of Common Stock, as such term is defined herein, at an exercise price of $0.01 per share, (ii) common stock Series A warrants to purchase 3,365,385 shares of Common Stock (the “Series A Common Warrants”) and (iii) common stock Series B warrants to purchase 3,365,385 shares of Common Stock (the “Series B Common Warrants”, and together with the Series A Common Warrants, the “Common Warrants”). The 1,530,769 Shares to be sold by the Company are called the “Firm Shares” and, collectively with the Pre-Funded Warrants and the Common Warrants, the “Firm Securities.” In addition, the Company has grante
